Concepts (330)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Soil | 13 | 2026 | 76 | 6.080 |
Why?
|
| Intestinal Diseases, Parasitic | 13 | 2026 | 43 | 5.300 |
Why?
|
| Helminths | 13 | 2026 | 53 | 4.730 |
Why?
|
| Helminthiasis | 13 | 2026 | 84 | 4.270 |
Why?
|
| Parasites | 9 | 2025 | 33 | 3.990 |
Why?
|
| Real-Time Polymerase Chain Reaction | 17 | 2026 | 526 | 3.670 |
Why?
|
| Feces | 25 | 2026 | 721 | 2.680 |
Why?
|
| DNA, Helminth | 5 | 2024 | 23 | 2.300 |
Why?
|
| Strongyloidiasis | 8 | 2025 | 52 | 1.820 |
Why?
|
| Strongyloides stercoralis | 11 | 2025 | 25 | 1.800 |
Why?
|
| Anthelmintics | 4 | 2025 | 56 | 1.670 |
Why?
|
| Chagas Disease | 4 | 2025 | 320 | 1.660 |
Why?
|
| DNA, Protozoan | 6 | 2025 | 26 | 1.620 |
Why?
|
| Coinfection | 7 | 2026 | 187 | 1.530 |
Why?
|
| Rural Population | 10 | 2026 | 276 | 1.480 |
Why?
|
| Trypanosoma cruzi | 4 | 2025 | 256 | 1.230 |
Why?
|
| Trichuris | 4 | 2025 | 26 | 1.230 |
Why?
|
| Hookworm Infections | 4 | 2024 | 127 | 1.190 |
Why?
|
| Animals | 48 | 2026 | 33912 | 1.170 |
Why?
|
| Antigens, Protozoan | 2 | 2025 | 77 | 1.100 |
Why?
|
| Toxocara | 2 | 2026 | 16 | 1.090 |
Why?
|
| Albendazole | 2 | 2025 | 26 | 1.090 |
Why?
|
| Trichuriasis | 2 | 2025 | 31 | 1.060 |
Why?
|
| Taenia solium | 3 | 2015 | 13 | 1.000 |
Why?
|
| Soil Microbiology | 2 | 2026 | 19 | 1.000 |
Why?
|
| Dengue | 2 | 2025 | 125 | 1.000 |
Why?
|
| Sensitivity and Specificity | 14 | 2025 | 2085 | 1.000 |
Why?
|
| Acanthamoeba | 1 | 2026 | 9 | 0.980 |
Why?
|
| Ascomycota | 1 | 2026 | 28 | 0.930 |
Why?
|
| HIV Infections | 6 | 2026 | 2049 | 0.890 |
Why?
|
| Leishmaniasis | 1 | 2025 | 41 | 0.880 |
Why?
|
| Neurocysticercosis | 2 | 2015 | 27 | 0.880 |
Why?
|
| Dog Diseases | 1 | 2025 | 58 | 0.870 |
Why?
|
| Ivermectin | 1 | 2024 | 8 | 0.870 |
Why?
|
| Hemoglobins | 1 | 2025 | 286 | 0.810 |
Why?
|
| Sanitation | 2 | 2025 | 15 | 0.760 |
Why?
|
| Prevalence | 11 | 2025 | 2701 | 0.740 |
Why?
|
| Brugia malayi | 1 | 2022 | 40 | 0.710 |
Why?
|
| Isosporiasis | 1 | 2021 | 3 | 0.710 |
Why?
|
| Giardia lamblia | 5 | 2023 | 11 | 0.700 |
Why?
|
| Ecuador | 6 | 2025 | 15 | 0.690 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 315 | 0.680 |
Why?
|
| Mycobacterium tuberculosis | 5 | 2024 | 430 | 0.670 |
Why?
|
| Vaccines | 1 | 2026 | 388 | 0.660 |
Why?
|
| Diarrhea | 2 | 2023 | 301 | 0.660 |
Why?
|
| Eosinophilia | 2 | 2021 | 112 | 0.660 |
Why?
|
| Intestines | 3 | 2020 | 587 | 0.650 |
Why?
|
| Humans | 61 | 2026 | 131163 | 0.650 |
Why?
|
| Poverty | 2 | 2024 | 462 | 0.650 |
Why?
|
| Artificial Intelligence | 1 | 2026 | 369 | 0.650 |
Why?
|
| Beds | 1 | 2020 | 9 | 0.630 |
Why?
|
| Parasite Egg Count | 5 | 2024 | 28 | 0.630 |
Why?
|
| Sarcoma, Kaposi | 1 | 2021 | 129 | 0.630 |
Why?
|
| Vaccination | 1 | 2026 | 1060 | 0.630 |
Why?
|
| Dust | 1 | 2020 | 32 | 0.620 |
Why?
|
| Vitamin B 12 | 1 | 2020 | 59 | 0.620 |
Why?
|
| Ascaris lumbricoides | 4 | 2026 | 19 | 0.610 |
Why?
|
| Family Characteristics | 1 | 2020 | 93 | 0.600 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 239 | 0.590 |
Why?
|
| Malaria, Falciparum | 2 | 2026 | 58 | 0.580 |
Why?
|
| Organ Transplantation | 1 | 2020 | 175 | 0.550 |
Why?
|
| Parasite Load | 1 | 2017 | 31 | 0.530 |
Why?
|
| Tuberculosis | 5 | 2024 | 550 | 0.530 |
Why?
|
| Ancylostomatoidea | 2 | 2024 | 60 | 0.490 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2026 | 842 | 0.490 |
Why?
|
| Inflammation | 5 | 2025 | 1489 | 0.480 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2024 | 69 | 0.470 |
Why?
|
| Pilot Projects | 5 | 2025 | 1445 | 0.470 |
Why?
|
| Child | 19 | 2026 | 26341 | 0.460 |
Why?
|
| DNA | 2 | 2022 | 1399 | 0.460 |
Why?
|
| Hypereosinophilic Syndrome | 2 | 2013 | 8 | 0.460 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 2024 | 238 | 0.440 |
Why?
|
| Antibodies, Protozoan | 2 | 2025 | 102 | 0.440 |
Why?
|
| Developed Countries | 1 | 2014 | 43 | 0.430 |
Why?
|
| Female | 29 | 2026 | 70963 | 0.430 |
Why?
|
| Emigration and Immigration | 1 | 2014 | 80 | 0.420 |
Why?
|
| Plasmodium falciparum | 2 | 2026 | 81 | 0.400 |
Why?
|
| Parasitic Diseases | 1 | 2014 | 59 | 0.400 |
Why?
|
| Alabama | 3 | 2025 | 43 | 0.400 |
Why?
|
| Cysticercosis | 1 | 2013 | 21 | 0.390 |
Why?
|
| Global Health | 2 | 2017 | 626 | 0.390 |
Why?
|
| Argentina | 3 | 2026 | 54 | 0.390 |
Why?
|
| Adult | 20 | 2026 | 31282 | 0.390 |
Why?
|
| Brain Edema | 1 | 2013 | 66 | 0.390 |
Why?
|
| Granuloma | 1 | 2013 | 59 | 0.380 |
Why?
|
| Child, Preschool | 12 | 2026 | 15110 | 0.380 |
Why?
|
| Developing Countries | 1 | 2014 | 305 | 0.360 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2013 | 333 | 0.360 |
Why?
|
| Calcinosis | 1 | 2013 | 180 | 0.350 |
Why?
|
| Male | 25 | 2026 | 64957 | 0.350 |
Why?
|
| Serologic Tests | 3 | 2025 | 122 | 0.350 |
Why?
|
| Antibodies, Helminth | 4 | 2025 | 131 | 0.350 |
Why?
|
| Neglected Diseases | 1 | 2014 | 152 | 0.350 |
Why?
|
| Cryptosporidium | 3 | 2017 | 27 | 0.340 |
Why?
|
| Schistosomiasis | 2 | 2024 | 51 | 0.340 |
Why?
|
| Environment | 2 | 2024 | 149 | 0.340 |
Why?
|
| Latin America | 2 | 2026 | 110 | 0.330 |
Why?
|
| Giardiasis | 2 | 2023 | 11 | 0.330 |
Why?
|
| Ancylostomiasis | 2 | 2024 | 62 | 0.330 |
Why?
|
| Young Adult | 8 | 2025 | 10103 | 0.330 |
Why?
|
| Adolescent | 11 | 2025 | 20987 | 0.320 |
Why?
|
| Middle Aged | 16 | 2026 | 28601 | 0.320 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2024 | 166 | 0.320 |
Why?
|
| Urban Population | 4 | 2026 | 287 | 0.310 |
Why?
|
| Anti-Infective Agents | 2 | 2022 | 266 | 0.300 |
Why?
|
| Uganda | 4 | 2026 | 85 | 0.290 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2025 | 787 | 0.290 |
Why?
|
| Bacterial Translocation | 2 | 2025 | 30 | 0.290 |
Why?
|
| Antigens, Helminth | 2 | 2025 | 187 | 0.280 |
Why?
|
| Necator americanus | 3 | 2025 | 93 | 0.270 |
Why?
|
| Anemia, Sickle Cell | 1 | 2012 | 334 | 0.270 |
Why?
|
| Blastocystis | 3 | 2025 | 6 | 0.270 |
Why?
|
| Seizures | 1 | 2013 | 890 | 0.270 |
Why?
|
| Ancylostoma | 3 | 2024 | 100 | 0.270 |
Why?
|
| Emigrants and Immigrants | 3 | 2025 | 169 | 0.250 |
Why?
|
| Ascariasis | 2 | 2018 | 76 | 0.250 |
Why?
|
| Toxocara canis | 1 | 2026 | 8 | 0.250 |
Why?
|
| Infant | 5 | 2025 | 13352 | 0.240 |
Why?
|
| Seroepidemiologic Studies | 2 | 2025 | 158 | 0.240 |
Why?
|
| Cross-Sectional Studies | 5 | 2025 | 3829 | 0.240 |
Why?
|
| Waste Disposal, Fluid | 1 | 2025 | 7 | 0.240 |
Why?
|
| Recombinant Proteins | 3 | 2025 | 1319 | 0.230 |
Why?
|
| DNA, Fungal | 1 | 2026 | 75 | 0.230 |
Why?
|
| Environmental Monitoring | 1 | 2026 | 99 | 0.230 |
Why?
|
| Entamoeba histolytica | 2 | 2017 | 10 | 0.230 |
Why?
|
| Sputum | 2 | 2024 | 113 | 0.230 |
Why?
|
| Necatoriasis | 1 | 2025 | 39 | 0.230 |
Why?
|
| Texas | 3 | 2025 | 3686 | 0.230 |
Why?
|
| Species Specificity | 3 | 2017 | 470 | 0.230 |
Why?
|
| Immunoglobulin G | 2 | 2025 | 786 | 0.230 |
Why?
|
| Sewage | 1 | 2025 | 10 | 0.230 |
Why?
|
| Peru | 1 | 2025 | 54 | 0.220 |
Why?
|
| Leishmania | 1 | 2025 | 34 | 0.220 |
Why?
|
| Public Opinion | 1 | 2026 | 64 | 0.220 |
Why?
|
| Protozoan Infections | 1 | 2025 | 15 | 0.220 |
Why?
|
| South Carolina | 1 | 2024 | 10 | 0.210 |
Why?
|
| Schistosoma | 1 | 2024 | 13 | 0.210 |
Why?
|
| Mississippi | 1 | 2024 | 35 | 0.210 |
Why?
|
| Bacteria | 2 | 2026 | 521 | 0.210 |
Why?
|
| Dogs | 1 | 2025 | 613 | 0.210 |
Why?
|
| Longitudinal Studies | 2 | 2026 | 1490 | 0.210 |
Why?
|
| Louisiana | 1 | 2024 | 137 | 0.210 |
Why?
|
| Mexico | 1 | 2024 | 190 | 0.210 |
Why?
|
| Dengue Virus | 1 | 2025 | 135 | 0.210 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2026 | 227 | 0.200 |
Why?
|
| Social Media | 1 | 2026 | 120 | 0.200 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 1280 | 0.190 |
Why?
|
| Water | 1 | 2024 | 186 | 0.190 |
Why?
|
| Pyrethrins | 1 | 2022 | 9 | 0.190 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 29 | 0.190 |
Why?
|
| Arboviruses | 1 | 2022 | 25 | 0.190 |
Why?
|
| Receptors, Interleukin-5 | 1 | 2022 | 5 | 0.180 |
Why?
|
| Insecticides | 1 | 2022 | 46 | 0.180 |
Why?
|
| Interleukin-5 | 1 | 2022 | 49 | 0.180 |
Why?
|
| Isospora | 1 | 2021 | 3 | 0.180 |
Why?
|
| BCG Vaccine | 2 | 2022 | 105 | 0.180 |
Why?
|
| Aedes | 1 | 2022 | 103 | 0.170 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2021 | 45 | 0.170 |
Why?
|
| Rabbits | 1 | 2022 | 575 | 0.170 |
Why?
|
| Zika Virus | 1 | 2022 | 150 | 0.160 |
Why?
|
| Mozambique | 3 | 2026 | 21 | 0.160 |
Why?
|
| Intestinal Mucosa | 1 | 2025 | 771 | 0.160 |
Why?
|
| Blastocystis Infections | 1 | 2020 | 5 | 0.160 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2020 | 9 | 0.160 |
Why?
|
| Zika Virus Infection | 1 | 2022 | 173 | 0.160 |
Why?
|
| RNA Interference | 1 | 2022 | 491 | 0.160 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2020 | 12 | 0.160 |
Why?
|
| Environmental Microbiology | 1 | 2020 | 15 | 0.160 |
Why?
|
| Eosinophils | 1 | 2020 | 122 | 0.150 |
Why?
|
| Genes, Bacterial | 1 | 2020 | 215 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2026 | 919 | 0.150 |
Why?
|
| Metagenomics | 1 | 2020 | 116 | 0.140 |
Why?
|
| Colombia | 3 | 2024 | 51 | 0.140 |
Why?
|
| Genetic Variation | 1 | 2025 | 1559 | 0.140 |
Why?
|
| Schistosoma haematobium | 1 | 2018 | 16 | 0.140 |
Why?
|
| Mass Drug Administration | 1 | 2018 | 14 | 0.130 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 362 | 0.130 |
Why?
|
| Microbiota | 1 | 2023 | 438 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2024 | 12936 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 2904 | 0.130 |
Why?
|
| Th1 Cells | 1 | 2018 | 158 | 0.130 |
Why?
|
| Microscopy | 2 | 2020 | 118 | 0.130 |
Why?
|
| Risk Factors | 3 | 2025 | 11074 | 0.130 |
Why?
|
| Cohort Studies | 4 | 2026 | 5063 | 0.130 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2550 | 0.120 |
Why?
|
| Entamoeba | 1 | 2016 | 3 | 0.120 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 256 | 0.120 |
Why?
|
| Aged | 4 | 2025 | 21025 | 0.110 |
Why?
|
| Linear Models | 1 | 2017 | 688 | 0.110 |
Why?
|
| Head Movements | 1 | 2015 | 18 | 0.110 |
Why?
|
| Vertigo | 1 | 2015 | 35 | 0.110 |
Why?
|
| United States | 4 | 2015 | 12072 | 0.110 |
Why?
|
| Cerebral Ventricles | 1 | 2015 | 80 | 0.110 |
Why?
|
| Africa | 1 | 2014 | 135 | 0.110 |
Why?
|
| Asia | 1 | 2014 | 124 | 0.110 |
Why?
|
| Headache | 1 | 2015 | 107 | 0.110 |
Why?
|
| Vomiting | 1 | 2015 | 103 | 0.100 |
Why?
|
| Parasitology | 1 | 2014 | 7 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 500 | 0.100 |
Why?
|
| DNA Primers | 2 | 2013 | 599 | 0.100 |
Why?
|
| Cysticercus | 1 | 2013 | 2 | 0.100 |
Why?
|
| Europe | 1 | 2014 | 365 | 0.100 |
Why?
|
| Mali | 1 | 2013 | 13 | 0.100 |
Why?
|
| Empirical Research | 1 | 2013 | 10 | 0.100 |
Why?
|
| Poverty Areas | 2 | 2025 | 37 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2025 | 6459 | 0.100 |
Why?
|
| Honduras | 2 | 2025 | 25 | 0.100 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 129 | 0.090 |
Why?
|
| Data Collection | 1 | 2014 | 370 | 0.090 |
Why?
|
| Antinematodal Agents | 1 | 2012 | 11 | 0.090 |
Why?
|
| India | 1 | 2013 | 234 | 0.090 |
Why?
|
| Sierra Leone | 1 | 2012 | 19 | 0.090 |
Why?
|
| Health Status | 1 | 2014 | 378 | 0.090 |
Why?
|
| North America | 1 | 2013 | 255 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2025 | 17753 | 0.090 |
Why?
|
| Syndrome | 1 | 2015 | 1155 | 0.090 |
Why?
|
| High-Throughput Screening Assays | 1 | 2013 | 119 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 732 | 0.090 |
Why?
|
| Neuroimaging | 1 | 2015 | 385 | 0.090 |
Why?
|
| Biomarkers | 3 | 2025 | 3385 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2012 | 195 | 0.090 |
Why?
|
| DNA, Bacterial | 2 | 2024 | 481 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2018 | 1077 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2013 | 1246 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 4066 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 218 | 0.080 |
Why?
|
| Zoonoses | 2 | 2024 | 52 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 289 | 0.080 |
Why?
|
| Cytokines | 2 | 2026 | 1339 | 0.080 |
Why?
|
| Recurrence | 1 | 2013 | 1489 | 0.070 |
Why?
|
| Hypersensitivity | 1 | 2012 | 227 | 0.070 |
Why?
|
| C-Reactive Protein | 2 | 2025 | 450 | 0.070 |
Why?
|
| Acute Disease | 1 | 2012 | 1153 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 6797 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 663 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1882 | 0.060 |
Why?
|
| Genotype | 1 | 2012 | 2595 | 0.060 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2025 | 53 | 0.060 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2025 | 34 | 0.060 |
Why?
|
| Proof of Concept Study | 1 | 2025 | 40 | 0.060 |
Why?
|
| Water Purification | 1 | 2025 | 20 | 0.060 |
Why?
|
| Drinking Water | 1 | 2025 | 15 | 0.060 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2025 | 38 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2018 | 544 | 0.060 |
Why?
|
| Eosinophil Cationic Protein | 1 | 2004 | 1 | 0.060 |
Why?
|
| Schistosoma mansoni | 1 | 2004 | 25 | 0.050 |
Why?
|
| Immunoassay | 1 | 2025 | 126 | 0.050 |
Why?
|
| Schistosomiasis mansoni | 1 | 2004 | 24 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2020 | 1447 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2026 | 377 | 0.050 |
Why?
|
| Pets | 1 | 2024 | 19 | 0.050 |
Why?
|
| Giardia | 1 | 2023 | 1 | 0.050 |
Why?
|
| Tanzania | 1 | 2024 | 68 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2025 | 410 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2025 | 420 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3763 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 294 | 0.050 |
Why?
|
| Brain | 1 | 2015 | 3175 | 0.050 |
Why?
|
| Phenazines | 1 | 2022 | 9 | 0.050 |
Why?
|
| Alginates | 1 | 2022 | 24 | 0.050 |
Why?
|
| Insecticide Resistance | 1 | 2022 | 30 | 0.050 |
Why?
|
| Tryptophan | 1 | 2022 | 84 | 0.050 |
Why?
|
| Mucins | 1 | 2022 | 71 | 0.050 |
Why?
|
| Mosquito Vectors | 1 | 2022 | 34 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 61 | 0.040 |
Why?
|
| Nitriles | 1 | 2022 | 163 | 0.040 |
Why?
|
| Swine | 1 | 2025 | 1186 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 192 | 0.040 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2022 | 194 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2020 | 35 | 0.040 |
Why?
|
| Gene Expression | 1 | 2004 | 1481 | 0.040 |
Why?
|
| New York City | 1 | 2020 | 59 | 0.040 |
Why?
|
| Spatial Analysis | 1 | 2020 | 26 | 0.040 |
Why?
|
| Chicago | 1 | 2020 | 22 | 0.040 |
Why?
|
| Antitubercular Agents | 1 | 2022 | 275 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2025 | 991 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2018 | 65 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2018 | 86 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2018 | 74 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2018 | 144 | 0.030 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2018 | 38 | 0.030 |
Why?
|
| Timor-Leste | 1 | 2017 | 1 | 0.030 |
Why?
|
| World Health Organization | 1 | 2018 | 118 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 889 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2017 | 132 | 0.030 |
Why?
|
| Program Development | 1 | 2018 | 179 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 2017 | 125 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2017 | 236 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2017 | 192 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 154 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1118 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2018 | 401 | 0.030 |
Why?
|
| Phylogeny | 1 | 2017 | 689 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 639 | 0.030 |
Why?
|
| Mice | 3 | 2023 | 18301 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2023 | 4738 | 0.020 |
Why?
|
| Leukemic Infiltration | 1 | 2013 | 9 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2018 | 2885 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 4697 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 1267 | 0.020 |
Why?
|
| Animal Structures | 1 | 2011 | 8 | 0.020 |
Why?
|
| Alum Compounds | 1 | 2011 | 41 | 0.020 |
Why?
|
| HIV | 1 | 2012 | 174 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1295 | 0.020 |
Why?
|
| Larva | 1 | 2011 | 243 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2465 | 0.020 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 155 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2023 | 8635 | 0.020 |
Why?
|
| Viral Load | 1 | 2012 | 416 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2012 | 497 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 301 | 0.020 |
Why?
|
| Skin | 1 | 2013 | 545 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 393 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 978 | 0.020 |
Why?
|
| HIV-1 | 1 | 2012 | 490 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2018 | 2406 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 1483 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5196 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2004 | 234 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 292 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1722 | 0.010 |
Why?
|
| Selection, Genetic | 1 | 2004 | 150 | 0.010 |
Why?
|
| Spleen | 1 | 2004 | 258 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2004 | 582 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2004 | 644 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 2395 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 2730 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 3464 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2004 | 1692 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 1796 | 0.010 |
Why?
|